4 results
Primary objectivesPart A: To determine the feasibility of Laromustine when given at three possible dose levels together with standard induction cycles I and II in patients with AML/ RAEB with IPSS³1.5 in a prospective comparison to standard…
Primary Efficacy Objective: To define the minimum effective dose (MED) of the oral dose of E4 by evaluating changes in frequency and in severity of moderate to severe vasomotor symptoms (VMS) within each treatment arm at week 4 and 12. Secondary…
To evaluate the safety and clinical utility of PEF treatment of advanced stage or metastatic cancer following progression on immunotherapy
To evaluate the safety and initial feasibility of PEF treatment of NSCLC tumors prior to surgical resection.